Lanzillo, Roberta <br/><br/>
Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a.  [electronic resource] 

 -  Clinical immunology (Orlando, Fla.)  10 2017 
 - 249-253 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1521-7035 
<br/><br/><label>Standard No.: </label>10.1016/j.clim.2017.08.011  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--therapeutic use<br/>Biomarkers--blood<br/>Humans<br/>Interferon beta-1a--therapeutic use<br/>Multiple Sclerosis, Relapsing-Remitting--blood<br/>Predictive Value of Tests<br/>Transcriptome--immunology